Total Results: 175
Researchers and patients are critical of drugs being brought onto the market that are expensive but offer little advantage in the fight against cancer. Meanwhile, Politico Pro looks at a new instance of an old drug getting approval for treating a rare disease, and pharmacy managers are looking for a way to explain their business.
The FDA has approved dozens of new cancer medications in recent years, but few offer the benefits that patients seek.
Empujados por defensores de pacientes que quieren acceso temprano a los medicamentos, la FDA ha aprobado una ráfaga de drogas oncológicas en los últimos años, Pero pocas de estas drogas han permitido a pacientes con una esperanza de vida limitada, vivir por años.
A selection of opinions on health care from around the country.
“Such a steep rise in the cost of this drug threatens to price-out families and communities that depend on naloxone to save lives,” the senators wrote to the drugmaker.
In other pharmaceutical industry news, Gilead Sciences’ revenue problem, a status check of Food and Drug Administration user fees and Vice President Mike Pence’s position on right-to-try laws.
Read recent commentaries about drug-cost issues.
News outlets report on stories related to pharmaceutical drug pricing.
Backing of the legislation is part of an overall push from the president to streamline the Food and Drug Administration. In other news, the agency says it will stop redacting information in resumes submitted by experts who serve on its advisory committees.
Prescription pain pills are strong sellers in this southeastern Kentucky region that’s long struggled with high rates of joblessness and poor health.
Kaiser Health News reporter Shefali Luthra discusses the controversy surrounding Kaleo, a company that makes a life-saving auto-injector for opioid drug overdoses on Weekend Edition.
Luke Whitbeck’s life was saved by a rare disease drug, but it costs $300,000 a year.
In an era where officials speak of deregulating and “streamlining” the Food and Drug Administration, a story of a blockbuster drug demonstrates the possible pitfalls of removing thorough vetting of experimental treatments. Meanwhile, the CEOs who met with the president reveal what happened behind closed doors, a California lawmaker takes aim at drug coupons, spiking insulin prices make diabetes one of the country’s most expensive diseases and more pharmaceutical news.
Also, drugmaker Amgen says tests of its controversial cholesterol drug show it performs well. But the company has not yet released the study’s data.
Big brand-name drug companies would likely support the legislation from Rep. Greg Walden, chairman of the House Energy and Commerce Committee, since it focuses on marketplace competition rather than government intervention. Meanwhile, a California lawmaker is moving to limit the use of coupons for drugs.
Each week, KHN’s Shefali Luthra finds interesting reads from around the Web.
Despite questions about Lupron’s lasting side effects and minimal study into its safety, the FDA sped approval of the drug to market. Years later, some young women are still living with the consequences.
A pesar de una tasa de fracaso de 99%, científicos que investigan el Alzheimer están avanzando con cientos de experimentos -y un gran impulso en dinero federal- para tratar de revertir una enfermedad mortal que los ha desconcertado por décadas.
Alzheimer’s researchers hold onto hope after another promising trial ends in disappointment.
Wood, who chairs the Assembly Health Committee, lays out his priorities for 2017.